Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dental pulp mesenchymal stem cells for COVID-19 pneumonia
IRCT20140911019125N8Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Sep 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of dental pulp mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (4 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Pulmonary condition, RNA expression of COVID-19 virus and 2 more. Started Sep 2020; status: completed.
02
Drugs
dental pulp mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20140911019125N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140911019125N8.